Rechercher des projets européens

28 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Doctoral Industrial School on Human Skin models for Staphylococcal infections (DISSection)

Date du début: 1 nov. 2016, Date de fin: 31 oct. 2020,

Staphylococcus aureus (S. aureus) is a major human pathogen and cutaneous infections are among the leading cause of emergency department visits. Unfortunately, S. aureus vaccine development is hindered by the lack of known correlates of protection. Three dimensional organotypic human skin models may represent a valid alternative to animal infection model.Indeed, S. aureus expresses several human-s ...
Voir le projet

 2

 TERMINÉ 

Doctoral Industrial School for Vaccine Design through Structural Mass Spectrometry (VADEMA)

Date du début: 1 nov. 2016, Date de fin: 31 oct. 2020,

Vaccines discovered from empirical approaches and consisting in killed, live-attenuated microorganisms or purified components have led to the successful control of many devastating diseases. Several novel technologies, such as recombinant DNA technology, glycoconjugation, reverse vaccinology have opened the possibility of designing vaccines previously considered impossible to make. Despite decades ...
Voir le projet

 2

 TERMINÉ 

Leveraging Pharmaceutical Sciences and Structural Biology Training to develop 21st Century Vaccines (PHA-ST-TRAIN-VAC)

Date du début: 1 juin 2016, Date de fin: 31 mai 2020,

Immunisation is one of the most cost-effective and proven tools to control and eliminate infectious diseases, saving millions of lives each year, yet key challenges remain in order to guarantee the future health of the expanding and ageing global population. For example, effective vaccines are still required for Respiratory Syncytial Virus (RSV) and Group B Streptococcus (GBS), both of which cause ...
Voir le projet

 2

 TERMINÉ 

Sustainable downstream processing of vaccines through incorporation of nanobiotechnologies : novel affinity ligands and biomimetic membranes (DiViNe)

Date du début: 1 mars 2015, Date de fin: 29 févr. 2020,

In the vaccine industry, downstream processing is of extreme importance. Prophylactic vaccines aim at protecting healthy people, so any contaminant has to be discarded with the most drastic measures. Such « negative » approach comes at the expense of the recovery of product : yields are poor, thereby inducing a high product cost. Processes are also complex, since they rely on multiple eliminations ...
Voir le projet

 6

 TERMINÉ 

Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protection (FLUCOP)

Date du début: 1 mars 2015, Date de fin: 29 févr. 2020,

Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Influenza infections affect all age groups but children and adults over the age of 65 are at most risk of developing severe disease.Vaccination is the most effective approach to reduce the impact of annual influenza outbreaks and potential pandemics, however, the ...
Voir le projet

 26

 TERMINÉ 

A training network for the rational design of the next generation of well-defined glycoconjugate vaccines (GLYCOVAX)

Date du début: 1 nov. 2015, Date de fin: 31 oct. 2019,

GLYCOVAX is a network for the education of promising young scientists who will learn how to rationally design a next generation of well-defined and innovative glycoconjugate vaccines to improve current preventive therapies and to tackle unmet medical needs. Glycoconjugate vaccines represent the key for success of vaccination in children. The covalent linkage to proteins renders carbohydrates able ...
Voir le projet

 12

 TERMINÉ 

New generation of carbohydrate-based vaccines via rational understanding of their immunological mechanism (NEWCARBOVAX)

Date du début: 13 juin 2016, Date de fin: 12 juin 2019,

Glycoconjugate vaccines have provided enormous health benefits globally, but they have been less successful in some populations at high risk for developing disease. They are composed by a sugar antigen covalently linked to a carrier protein. The traditional hypothesis of immune activation by glycoconjugate vaccines suggests that only peptides generated from glycoconjugate processing can be present ...
Voir le projet

 1

 TERMINÉ 

Accelerated Development of Vaccine benefit-risk Collaboration in Europe (ADVANCE)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,

Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to rapidly provide robust data on vaccine benefits and risks to support accelerated decision-making.Approach: To achieve this vision through a public-private partnership, ADVANCE partners 1. establish common grounds and rules for collaboration between public and ...
Voir le projet

 30

 TERMINÉ 

A multidisciplinary Doctoral Industrial School on novel preventive strategies against E. Coli infections (DISCO)

Date du début: 1 avr. 2014, Date de fin: 31 mars 2018,

The doctoral school proposed in DISCo originates from the common interest of Novartis Vaccines (NVD) and the French National Institute of Agronomical Research (INRA) in preventing E. coli infections. Both Institutes have a strong background in microbial pathogenesis, supported by a number of ongoing research programmes aimed at combating human infectious diseases. In particular, NVD, by using a hi ...
Voir le projet

 2

 TERMINÉ 

Improving Prostate Cancer Outcome with Vectored Vaccines (IMPROVE)

Date du début: 1 avr. 2014, Date de fin: 31 mars 2018,

A successful vaccine against cancer is most likely to work through the induction of potent CD8+ T cells that can successfully kill tumour cells. But achieving this has proved difficult and only low level responses are induced by current vaccine approaches. Nonetheless, two therapeutic immunisation strategies have shown partial success in targeting prostate cancer, and one recently reached licensur ...
Voir le projet

 5

 TERMINÉ 

Advanced Immunization Technologies (ADITEC)

Date du début: 1 oct. 2011, Date de fin: 30 sept. 2017,

Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in science and technology makes it possible to achieve what was previously deemed impossible. The scope of this project is to produce knowledge necessary to develop novel and ...
Voir le projet

 53

 TERMINÉ 

Structural Vaccinology in the design of bionanoparticles with multi-copy antigen display for vaccines with enhanced efficacy (SVNanoVax)

Date du début: 15 juin 2015, Date de fin: 14 juin 2017,

Vaccines are the most effective way to protect humans from infectious disease and may save over 2 million lives per year (Delany, 2013). A key issue for future vaccines is how to improve immunogenicity without reducing safety (Bachmann, 2010). Another challenge is that high antigen sequence variability enables pathogens to escape the host response. To overcome these challenges, this proposal combi ...
Voir le projet

 1

 TERMINÉ 

European Multicentre Tics in Children Studies (EMTICS)

Date du début: 1 déc. 2011, Date de fin: 31 mai 2017,

This project will undertake pre-clinical and cohort studies that address susceptibility factors for paediatric and adolescent tic disorders, with a particular focus on comorbid obsessive-compulsive symptomatology, from clinical, epidemiological, genetic, microbiological and immunological angles. EMTICS aims to elucidate the complex aetiology of the onset and clinical course of chronic tic disorder ...
Voir le projet

 33

 TERMINÉ 

The genetic basis of meningococcal and other life threatening bacterial infections of childhood (EUCLIDS)

Date du début: 1 déc. 2011, Date de fin: 31 mai 2017,

Bacterial infection is the major cause of disability and death in children worldwide. We will use meningococcal disease (MD) as a model to understand genetic factors underlying susceptibility and severity of childhood bacterial infection which will then be applied to other childhood infections. We have established cohorts of patients with MD in Central and Southern Europe (CE,SE), UK and Africa as ...
Voir le projet

 16

 TERMINÉ 

A Multi-Stage Malaria Vaccine (MultiMalVax)

Date du début: 1 oct. 2012, Date de fin: 31 mars 2017,

A highly effective malaria vaccine is a major goal of global health research and will likely require a multi-stage product. MultiMalVax will develop a highly effective multi-stage malaria vaccine to the point of proof-of-concept phase II testing in Europe, prior to trials in malaria-endemic areas.Remarkable recent advances in vaccine design for all four stages of the P. falciparum parasite’s life- ...
Voir le projet

 6

 TERMINÉ 

Host-microbe interactions in health and disease. Interface with the immune system (HOMIN)

Date du début: 1 avr. 2013, Date de fin: 31 mars 2017,

"HOMIN is designed as an advanced education and research program meant to train junior investigators possessing medical and/or scientific educational backgrounds to become future leading scientists in academic institutions, private companies, or administration.The HOMIN objectives are:1. To provide multidisciplinary and intersectorial scientific education through the study of host-microbe interact ...
Voir le projet

 5

 TERMINÉ 

Biomarkers For Enhanced Vaccine Safety (BIOVACSAFE)

Date du début: 1 mars 2012, Date de fin: 31 déc. 2016,

BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised into focused Activity Cores to generate knowledge and tools to benchmark licensed vaccine reactogenicity, and create practical and generalizable guidelines and techniques to enhance immunosafety of novel vaccines from pre-development to post-marketing surveil ...
Voir le projet

 24

 TERMINÉ 

Training network for next generation vaccinologists (VACTRAIN)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,

Vaccines are the most cost-effective health interventions available (WHO). The impact of vaccination on the health of the world’s population cannot be overstressed. Vaccinolgy is the multidisciplinary discipline of developing vaccine interventions it combines knowledge from basic sciences, medical sciences, public health and social sciences. Ideally a vaccinologists would be able to have a general ...
Voir le projet

 9

 TERMINÉ 

Development of RApid Point-of-Care test Platforms for Infectious Diseases (RAPP-ID)

Date du début: 1 avr. 2011, Date de fin: 30 sept. 2016,

RAPP-ID (“Development of RApid Point-of-Care test Platforms for Infectious Diseases”) will develop a Point-of-Care Test (POCT) for rapid (hospital
Voir le projet

 20

 TERMINÉ 

Self-amplifying RNA technology applied to the development of a universal influenza vaccine (SAMUFLU)

Date du début: 1 avr. 2014, Date de fin: 31 mars 2016,

Influenza (Flu) virus infections lead to thousands of deaths annually worldwide and billions of dollars of economic burden. Vaccination is the primary strategy for Flu prevention; however, effective protection requires a perfect match with the seasonal circulating strains. Seasonal vaccines target the hemagglutinin (HA) and neuraminidase (NA) proteins of the two predominant A and one B circulating ...
Voir le projet

 1

 TERMINÉ 

Structural Vaccinology to drive the design and optimization of protein antigens for a multicomponent vaccine against Staphylococcus aureus (SV-STAPH-VAX)

Date du début: 1 mars 2014, Date de fin: 29 févr. 2016,

Staphylococcus aureus is one of the most important bacterial pathogens causing human death and disease on a global scale (Klevens, 2007). The rapid generation of antibiotic resistance, coupled with the frequency and severity of staphylococcal disease, underlie the increasing medical need to combat S. aureus infections. As an alternative to inadequate antibiotic therapies, we are dedicating efforts ...
Voir le projet

 1

 TERMINÉ 

Regulation of Expression of Staphylococcus aureus Vaccine Antigen Candidates (RESTAVAC)

Date du début: 1 sept. 2013, Date de fin: 31 août 2015,

Staphylococcus aureus is a commensal of the human skin and nares, and a major cause of skin, and soft tissue as well as invasive infections. Bacterial pathogenicity results from a complex interplay of virulence factors with regulatory systems that respond to multiple external signals from the host environment and the bacterial population. Currently no vaccine against S. aureus is available. Novart ...
Voir le projet

 1

 TERMINÉ 

European Initiative for basic research in Microbiology and Infectious Diseases (EIMID ITN)

Date du début: 1 oct. 2010, Date de fin: 30 sept. 2014,

The overall objective of EIMID-ITN is to train ten early stage researchers to join the next generation of world experts in the biology of infectious diseases and specifically in the mechanisms of host-pathogen interaction. The project will be carried out within the highly successful European collaboration EIMID (European Initiative for Basic Research in Microbiology and Infectious Diseases) that b ...
Voir le projet

 6

 TERMINÉ 

A Clostridal Biology Network to Facilitate European-wide Medical Countermeasures and Commercial Exploitation (CLOSTNET)

Date du début: 1 sept. 2009, Date de fin: 31 août 2013,

"There is an urgent need to better understand the basic biology of Clostridium as a prerequisite for both countering the diseases they cause (C.difficile, C.perfringens and C.botulinum), and exploiting their beneficial properties in industry (biofuels by C.acetobutylicum) and medicine (cancer therapy by C.sporogenes). Attainment of this goal is being impeded because: (i) European research efforts ...
Voir le projet

 14

 TERMINÉ 

Impact of adjuvants on T cell differentiation after Influenza Vaccination analyzed at the Single Cell Level (TCDIFLU)

Date du début: 1 mars 2011, Date de fin: 28 févr. 2013,

"Mutating viruses and resistance to drugs are the major challenges to overcome in influenza (flu) prevention and treatment. Virus-neutralizing antibodies are the key for protection against flu infection, but flu-specific CD4+ and CD8+ T cells play a significant role by providing help to B cells and in viral clearance, respectively.There are many vaccines against flu infection approved for human us ...
Voir le projet

 1

 TERMINÉ 

European Initiative for basic research in Microbiology and Infectious Diseases - IAPP (EIMID-IAPP)

Date du début: 1 déc. 2008, Date de fin: 30 nov. 2012,

"The EIMID-IAPP training programme is part of the European Initiative for Basic Research in Microbiology and Infectious Diseases (EIMID), created in 2003 by scientists of five European centres of excellence (the Max Planck Institute for Infection Biology in Berlin, the CMMI at Imperial College in London, the Institut Pasteur in Paris, the Karolinska Institutet in Stockholm; and the vaccine company ...
Voir le projet

 7

 TERMINÉ 

In search of new cytomegalovirus vaccine antigens (MEGALOVAX)

Date du début: 1 juil. 2010, Date de fin: 30 juin 2012,

"Aim of the project is to search for antigens that induce neutralizing antibodies in mice, which prevent entry of Human cytomegalovirus (HCMV) in vitro, and to characterize the identified candidate antigen with respect to its function. We will employ the “reverse vaccinology approach” with two robust technological platforms. A published genomic DNA sequence of HCMV has been analyzed and identified ...
Voir le projet

 1

 TERMINÉ 

Design of a vaccine to immunize neonates against GBS infections through a durable maternal immune response (DEVANI)

Date du début: 1 janv. 2008, Date de fin: 30 juin 2011,

"Direct vaccination cannot prevent diseases that affect neonates in the first days of life. Group B Streptococcus (GBS) is the major cause of neonatal septicemia and meningitis affecting up to one in every thousand live births. Over 80% of cases occur in the first 7 days after birth and the remaining 20% of disease occurs between 8-90 days after birth. Studies carried out in the USA indicate that ...
Voir le projet

 10